Clinical trial
Caffeine for Excessive Daytime Somnolence in Parkinson's Disease
NCT00459420 · Ron Postuma, Other · Completed
Key facts
| NCT number | NCT00459420 |
|---|---|
| Title | Caffeine for Excessive Daytime Somnolence in Parkinson's Disease |
| Official title | Caffeine for Excessive Daytime Somnolence in Parkinson's Disease |
| Lead sponsor | Ron Postuma, Other |
| Collaborators | Canadian Institutes of Health Research (CIHR) University of Toronto |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Parkinson's Disease, Excessive Daytime Somnolence |
| Intervention type | Drug |
| Interventions | Caffeine 100-200 mg BID, placebo |
| Enrollment | 58 |
| Start date | Apr 1, 2007 |
| Primary completion | Jul 1, 2011 |
| Completion | Jul 1, 2011 |
| First posted | Apr 12, 2007 |
| Last update posted | Apr 16, 2015 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: